The UK Interstitial Cystitis (IC) Therapeutics market size stood at around USD 0.075 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
According to the Interstitial Cystitis Association (ICA), Interstitial cystitis (IC), is a bladder condition that usually consists of multiple symptoms. Interstitial Cystitis also called Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain, and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. With IC, these signals get mixed up and then patients feel the need to urinate more often and with smaller volumes of urine than most people.
About 90% of those who are affected are women. Patients of all ages can be affected, although women in their 20s and 40s are the most typically affected. The most commonly used methods to diagnose IC include physical examination, ultrasound/pelvic imaging, laboratory tests such as urinalysis, culture, cytology, potassium sensitivity test, etc. Although there is no cure, yet off-label medications and other therapies may offer some relief.
Market Growth Drivers
As there is a lack of approved drugs for the better IC treatment but only a few medications and other therapies may offer some relief such as has these two approved drugs are currently available in the UK, ELMIRON and RIMSO-50 (dimethyl sulfoxide) can be expected that they would augment the market during the forecast period.
So, there is a huge market potential for the newly approved drugs in this niche market segment for the effective cure of interstitial cystitis in the UK.
Studies suggested that females are 9 times more likely to be diagnosed with IC/PBS compared to males. Thus, the female gender is the most definitive risk factor for developing IC/PBS, hence this will propel the market during the forecast period.